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Abbreviations
ACR

Acute cellular rejection

AST

Aspartate aminotransferase

ALT

alanine aminotransferase

CNI

Calcineurin inhibitors

CS

Corticosteroids

CMV
DM

Cytomegalovirus
Diabetes mellitus

EC-MPS

Enteric-coated mycophenolate sodium

HCV

Hepatitis C virus

INR

International Normalized Ratio
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I-R

Ischemia-reperfusion injury

MAP

Mean arterial pressure

MMF

Mycophenolate mofetil

NGT

Naso-gastric tube

NODM

New onset- diabetes mellitus

POD

Post-operative day

OLT

Orthotopic liver transplantation

ABSTRACT

Background. Corticosteroids (CS) have always been part of the standard post-transplant
immunosuppression to prevent and treat rejection. However, CS are associated with
increased risk of infection, obesity, hypertension, hyperlipidemia, diabetes, and bone
necrosis. They have also been implicated in accelerating Hepatitis C (HCV) recurrence postliver transplantation (OLT). This study assesses the safety and efficacy of completely CSfree immunosuppressive regimen in adult OLT.
Methods. A 2-year, prospective, randomized study of CS or no-CS immunosuppressive
regimen with basiliximab, tacrolimus and enteric-coated mycophenolate sodium (EC-MPS)
was performed in 39 patients (CS=20, group A; No-CS=19, group B). The CS cohort
received intra-operative methylprednisolone 1 gram intravenously tapered and weaned off by
6 months. HCV patients had HCV PCR pre-OLT, 0.5, 1, 3, 6 months post-OLT. Protocol
liver biopsies were performed at OLT, 2 weeks, and 6 months post-OLT or when clinically
indicated.
Results. CS-responsive acute rejection occurred in one patient in each group. Patient survival
rates at 1 year (100% vs. 94%), 3 and 5 years (85% vs. 63%) post-OLT were similar between
group A and B, respectively. Death-censored graft survival rates at 1 year (100% vs. 100%),
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3 and 5 years (85% vs. 79%) were also similar between group A and B, respectively. The
risk of new onset DM, hypertension, hypercholesterolemia, and weight gain was similar
between 2 groups.
Conclusion. Complete CS-avoidance with basiliximab, calcineurin inhibitor (CNI), and ECMPS is safe and effective as CS-containing immunosuppressive regimen in adult OLT.

INTRODUCTION
Corticosteroids (CS) have always been an integral part of standard post-transplant
immunosuppression for prevention and treatment of rejection. First introduced in the early
1950s, CS have been used widely since the first successful orthotopic liver transplantation
(OLT) in 1967 (1).

CS exert potent immunosuppressive and anti-inflammatory effects

through their action on leukocytes by stimulation or inhibition of gene transcription, altering
gene expression responsible for mounting immune and inflammatory responses. However,
CS use has been shown to cause long-term adverse effects, which include diabetes, increased
susceptibility to infection, obesity, hypertension, hyperlipidemia, osteopenia, cataracts and
growth retardation in children. CS have also been implicated in accelerating Hepatitis C
(HCV) recurrence post-OLT (2-3). Consequently, several clinical trials which adopted early
CS reduction and cessation after OLT were conducted and showed no increase in safety risks
(4-6). In recent years, a small but increasing proportion of transplant centers, including our
group, have demonstrated that adult and pediatric OLT may be successfully performed with
CS minimization (7-11).
Prior to this study the standard immunosuppressive protocol at Thomas Jefferson
University Hospital (TJUH) for OLT recipients included basiliximab induction and CS
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intraoperatively, followed by calcineurin inhibitor (CNI), mycophenolate mofetil (MMF),
and CS maintenance therapy.

RESULTS
Between February 2006 and November 2007, forty adult OLT recipients were
enrolled in the study and 20 recipients were randomized to each group. One recipient in the
CS-free group required a re-transplantation for hepatic artery thrombosis on post-OLT day
16. Since he expired within 10 days after re-transplantation, follow up data was short and
untenable and therefore, he was excluded from the study analysis.
The mean overall follow-up was 47.3 months as of July 2011. Donor characteristics
were comparable between the two groups (Table 1). Other than a significantly higher mean
recipient age and longer mean hospital stay in group B compared to group A, recipient
demographics and peri-operative data were similar between the two groups. There were 3
outliers in group B with mean hospital stay of 67.7 (range: 43-89) days. One had a protracted
surgical ICU stay due to prolonged ventilator dependence, atrial fibrillation, and poor mental
status. Another patient had ventilator-dependent adult respiratory distress syndrome, hepatopulmonary syndrome, acute renal failure, sepsis, and massive colonic bleeding. The third
patient had a MELD score of 35 at OLT with hepato-renal syndrome (Table 1).
Primary end points
There was no significant difference in patient and death-censored graft survival rates
between the 2 groups. The 1-, 3-, and 5-year patient survival rates in group A and group B,
respectively were: 100% vs. 94%, 85% vs. 63%, and 85% vs. 63% (Figure1). The 1-, 3-, and
5-year graft survival rates in group A and B, respectively were: 100% vs. 100%, 85% vs.
79%, and 85% vs. 79% (Figure 2). There were 10 deaths, 3 in group A and 7 in group B. The
causes of death in group A were: cerebrovascular accident (n=1), and liver failure secondary
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to severe progressive HCV recurrence (n=2). In group B, the causes of death were: cerebrovascular accident (n=1), necrotizing pancreatitis post-endoscopic retrograde cholangiopancreatography (n=1), self-inflicted gun shot wound to the head (n=1), and liver failure
secondary to severe progressive HCV recurrence (n=4). The mean time to death from OLT
was 21.5 months in group A and 24.7 months in group B (p= ns). CS-responsive biopsyproven acute rejection occurred once in 1 patient (5%) in each group.
Secondary end points.
The mean peak aspartate aminotransferase (AST), alanine aminotransferase (ALT),
total bilirubin and international normalized ratio (INR) levels and the mean days to peak
post-OLT were similar between the 2 groups. The time to transaminase peak occurred on
POD 2 and POD 1 in groups A and B, respectively, while the mean time to INR peak was
<1day for both groups. Furthermore, there was no incidence of primary non-function in this
cohort (Table 2).
The mean weight decreased in group A and group B from baseline to one month postOLT. However, from 1-month to 1-year post-OLT, mean weight increased steadily in group
A but decreased in group B, although the difference was not significant. Mean cholesterol
levels were similar in both groups from baseline to 12 months post-OLT. The mean arterial
pressure (MAP) in group A increased from baseline to 3 months before they started to
decrease by 6 months post-OLT. Likewise, MAP in group B increased from baseline to 1
month before they trended downwards by the 3rd month post-OLT.

Mean FBS levels at

baseline, 1, 3, and 12 months post-OLT were similar, except at 6 months post-OLT when
FBS levels were significantly higher (p=0.02) in group A compared to group B. Eight
recipients in each group developed NODM with mean FBS levels (mg/dl) of 148 and 152 in
group A and B, respectively (Table 2).
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A total of 12 patients in each group developed bacterial infection. No single case of
CMV infection/disease was observed in the cohort. Furthermore, there was no recurrent HCC
or new malignancy noted on last follow-up.
There were more HCV recipients in group B (74%) than in group A (55%). We also
observed an earlier peak (1 vs. 3 months post-OLT) and higher HCV PCR levels (16 million
vs. 11.9 million, p=ns) in group A than in group B. However, the incidence and severity of
HCV recurrence were similar in both groups based on liver biopsy results. Anti-viral
treatment outcomes are listed in Table 3.
Mean tacrolimus trough levels (ng/ml) were similar at 1, 3, 6, and 12 month postOLT in group A (11.3, 9, 7.8, 7.5) and B (8.1, 7.8, 9.4, 6), respectively. The mean duration
on CS was 174 days in Group A. EC-MPS was given for a mean duration of 2.9 months postOLT in both groups. EC-MPS dose reduction was carried out for gastro-intestinal symptoms
(diarrhea, vomiting) in 4 patients in each group; and for neutropenia in 3 and 6 recipients in
group A and B, respectively. EC-MPS was discontinued for GI symptoms in 1 recipient in
each group; and for neutropenia in 2 and 1 recipient in group A and B, respectively.

DISCUSSION
Corticosteroids have been used widely for decades as part of immunosuppressive
therapy in OLT despite their various associated long term adverse effects. In an attempt to
reduce or avoid CS adverse effects, several transplant centers have successfully tried CS
minimization or early CS withdrawal protocols post-OLT (4-11) and have reported similar
graft failure rates with reduction and better control of hypertension, diabetes, obesity, and
hypercholesterolemia, which are major risk factors known to accelerate atherosclerotic heart
disease (10,12). In recent years, a few CS-free immunosuppressive protocols have been
proposed post-OLT (7-8, 13-19). Some CS-free protocols included the use of intra-operative
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dose of CS followed by post-OLT CS-free maintenance therapy (8, 20-24). Although CSfree protocols were reported to be safe compared to historical controls, these regimens have
not been widely adopted by many transplant programs. Our aim was to evaluate the safety
and

efficacy

of

complete

CS-avoidance

compared

to

standard

CS-containing

immunosuppressive regimen consisting of basiliximab induction and tacrolimus, EC-MPS
maintenance immunosuppression in adult OLT recipients.
The protective effect of CS treatment in ameliorating ischemia-reperfusion (I-R)
injury and reducing acute rejection in deceased-donor OLT has been verified in a prospective
randomized study (25). However, this approach was questioned by animal studies which
showed that CS given at the time of transplantation could enhance I-R injury by increasing
DNA fragmentation, and apoptosis after reperfusion (26), and by inhibiting TNF and IL-6
expression, which impairs cell-cycle progression, and hepatocyte regeneration (27). Our trial
showed no difference in the incidence of I-R injury between CS-containing and CS-free
groups, supporting Pirenne’s (10) findings that intra-operative high dose CS bolus has no
protective effect on I-R injury.

A recent meta-analysis of 19 randomized trials which compared CS-treated to CSfree immunosuppression reported that the CS-free groups demonstrated a trend toward lower
hypertension and statistically significant reduction in cholesterol levels and CMV infection
(28). Contrary to these results our prospective randomized trial did not show any difference
between the two groups in the incidence of hypertension, cholesterol levels or CMV
infection. Although not significant, our results showed a tendency toward increased weight
gain in the CS-treated group, which is an anticipated consequence of long term CS use. This
disparity may be explained by the heterogeneity of immunosuppressive protocols used by the
individual centers, the short period of follow up and the small sample size of the various
trials in the meta- analysis groups. The meta-analysis also suggested that the risk of NODM

9
would be markedly lower in the CS-free arm if CS were replaced with another
immunosuppressive agent such as an anti-IL2 antibody, polyclonal anti-T-cell antibody or
MMF, which was not demonstrated in our study. Our study also showed that FBS levels
were similar between groups except at 6 months post-OLT when they were higher in the CStreated group. The reason for this unexpectedly higher glucose level at 6 months is unclear
considering that most recipients in the CS-treated group were no longer on CS by 6 months
post-OLT.

Our study showed an overall low ACR rate of 5% and similar 1-, 3-, and 5-year
patient and graft survival rates between CS-containing and CS-free groups. These may be
attributed to the use of anti-IL2 induction in combination with dual CNI/MPA maintenance
immunotherapy.

HCV recurrence post-OLT is almost a universal phenomenon. The incidence of
histological HCV recurrence ranges from 14% to 72% (29-30). Furthermore, a severe
cholestatic type of recurrent HCV, characterized by rapid progression to graft failure
requiring re-transplantation within 2 years, has been reported in about 10% of HCV
recipients (31-32). Contrary to these findings, our study showed higher overall incidence of
histologic HCV recurrence (81%), and severe cholestatic HCV recurrence (28%).
Furthermore, although the mean PCR levels peaked higher and earlier in the steroid group
compared to steroid-free group, there was no difference in the incidence and severity of HCV
recurrence, treatment outcomes, and graft loss rates between the two groups. These findings
are consistent with the suggestions of Eghtesad et al. (33) that viremia or avoidance of
specific immunosuppressive drug such as CS is not critical in promoting accelerated HCV
recurrence

post-OLT.

Instead,

they

suggested

that

timing

and

continuity

of

immunosuppressive drugs post-OLT, which regulate the overall balance between virus
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distribution and immune responsiveness, are more important factors affecting treatment
outcomes in HCV recipients.

Mycophenolate mofetil has been one of the newer therapies in OLT in the last
decade. However, MMF has been associated with diarrhea, nausea, vomiting, abdominal
pain, etc. EC-MPS was developed in an effort to lessen these side effects. Renal transplant
studies have shown the use of EC-MPS to be as effective and as safe as MMF (34- 35).
However, studies on de novo use of EC-MPS in OLT recipients have been limited to
conversion from MMF to EC-MPS (36-38). One study analyzed and showed that EC-MPS
has similar efficacy to MMF as a primary immunosuppressant or as an MMF replacement in
OLT recipients (39). Our data showed that EC-MPS was well tolerated with similar
incidence of side effects between CS-treated and CS-free groups, most of which resolved
with dose reduction. Neutropenia was observed less frequently in the CS-treated group,
which could explain why over 90% in this group tolerated optimal dosing of EC-MPS. We
suggest that the low incidence of neutropenia in the CS-treated group may be related to the
effect of CS in increasing white blood cell count.

In this study, no recipient with autoimmune-mediated liver disorder, i.e., primary
biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis, was randomized
in the CS-free group. It is well recognized that this subgroup of recipients may develop
disease recurrence in the liver allograft and reported to have a higher incidence of acute and
chronic ACR and perhaps may benefit from continuous, long term CS immunoprophylaxis
(40-41). Consequently, extra caution should be exercised when selecting recipients who can
safely be included in a completely CS-free regimen.

In conclusion, our analysis suggests that complete CS avoidance in adult OLT using
basiliximab induction with CNI and EC-MPS maintenance is as safe and as effective as
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standard CS-containing immunosuppression when evaluating for graft function, acute
rejection, and patient and graft survival. Contrary to other studies, our results did not show
any significant difference between CS-treated and CS-free groups in the incidence of
hypertension, hypercholesterolemia, NODM, and weight gain. Furthermore, our data did not
validate the common belief that CS-free immunosuppression has a beneficial effect in
reducing the incidence, severity or degree of progression of HCV recurrence post-OLT.

MATERIALS AND METHODS
Institutional Review Board approval from TJUH was granted and informed consent
was obtained from all subjects enrolled in this study, conforming to the ethical guidelines of
the Declaration of Helsinki. Between February 2006 and November 2007, forty adult
recipients of deceased donor primary OLT at TJUH were enrolled into this prospective,
controlled, randomized, non-blinded, pilot trial. The primary objective was to assess the
efficacy and safety of a completely CS-free immunosuppressive regimen in OLT, by
comparing graft and patient survival rates and incidence and treatment of acute cellular
rejection (ACR), between recipients treated with and without CS. The secondary objective
was to compare the incidence of CS-related metabolic complications and HCV recurrence
between recipients treated with and without CS.

Common side effects associated with

enteric-coated mycophenolate sodium (EC-MPS) use, i.e., neutropenia and gastro-intestinal
symptoms, were also evaluated.

Inclusion criteria: adult recipients of primary cadaveric OLT between 18- 72 years
old, liver graft cold ischemia time of <20 hours, and women of childbearing potential with
negative pregnancy test.

The exclusion criteria included: multiple organ transplant
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recipients, women of childbearing potential not using the prescribed contraceptive
methods, and use of any other investigational agent within 30 days prior to enrollment.

All recipients received basiliximab 20 mg IV intra-operatively and on post-operative
day (POD) 4. Maintenance immunosuppression included tacrolimus and EC-MPS.
Tacrolimus was started at 0.10 mg/kg/day by mouth (PO) or nasogastric tube (NGT) in 2
divided doses, within 48 hrs after reperfusion. The dose was adjusted to achieve target trough
level 8-12 ng/ml in first month post-OLT, and 5-8 ng/ml, thereafter. All recipients received
MMF 1 g every 12 hours via NGT until they could take oral medications, after which they
were switched to EC-MPS 720 mg PO twice daily for three months post-OLT.

Recipients were randomized into either treatment arms: Control arm (group A) standard immunosuppression with CS; and CS-free arm (group B) - standard
immunosuppression without CS. Group A received methylprednisolone 1 g IV intraoperatively followed by a taper schedule as follows: methylprednisolone 50 mg IV every 6
hours on day 1; 40 mg IV every 6 hours on day 2; 30 mg IV every 6 hours on day 3; 20 mg
IV every 6 hours on day 4; 20 mg IV every 12 hours on days 5; and thereafter, prednisone 20
mg PO daily which was tapered off by 6 months post-OLT. Group A and B recipients were
on maintenance CNI monotherapy by 6 months and 3 months post-OLT, respectively.

All recipients received cytomegalovirus (CMV) prophylaxis with IV gancyclovir or
valgancyclovir 450 mg PO daily for at least 3 months. They also received prophylactic doses
of trimethoprim sulfa 3 times weekly and nystatin swish and swallow 3 times daily.

Liver biopsies were performed according to protocol intra-operatively, between days
7 and 21 post-OLT and at 3-6 months post-OLT, and when clinically indicated. For HCV (+)
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recipients, quantitative HCV RNA PCR serum levels were performed at baseline, 0.5, 1, 3,
and 6 months post-OLT.

Biopsy-proven ACR using the Banff Classification (42) was treated in both groups
with methylprednisolone 1 g IV followed by a 5-day CS taper as described above. For
recipients in group B who received CS for ACR, prednisone was tapered off by the third
month after CS initiation. The protocol also required a repeat biopsy if there was no
improvement in the liver function test at the end of CS taper.

A diagnosis of HCV recurrence was made based on liver biopsy findings and serum
HCV RNA titers. Recipients with HCV recurrence were treated according to TJUH protocol
as described below. Abnormal liver function tests were evaluated by hepatic ultrasound, and
percutaneous liver biopsy. The TJUH protocol follows the modified Scheuer scoring system
(43-44) to evaluate the need for anti-viral treatment in chronic hepatitis post-OLT. If the liver
biopsy shows total score of >4 for necro-inflammatory activity (greater than mild portal and
lobular inflammation) or > stage 1 (enlarged and fibrotic portal tracts), treatment with PegInterferon 180μg subcutaneously weekly for 2 weeks would be started. If the recipient
tolerates peg-interferon without hematologic or neuro-psychiatric complications, ribavirin is
added to Peg-interferon for a total duration of 48 weeks.

Weight, total cholesterol, fasting blood sugar (FBS), and mean arterial pressure
(MAP) levels were measured and recorded at baseline, 1, 3, 6 and 12 months post-OLT.
New onset diabetes mellitus (NODM) was defined as FBS ≥ 126 mg/dl (7 mmol/l), with
fasting defined as no caloric intake for at least 8 hours.

STATISTICAL ANALYSIS:

Statistical analysis was done to demonstrate

equivalence or non-inferiority of the CS-free immunosuppressive regimen compared to the
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standard protocol with CS for both primary and secondary end points. All continuous
variables were summarized with mean and standard error and all categorical variables
summarized as percentages. Statistical significance for each test was reported at p ≤ 0.05.
For continuous values, each group was compared using a two-tailed, independent Student’s ttest assuming equal or unequal variance based on the results of an F-test. Each categorical
variable was compared using a two-tailed Fisher’s exact test. Survival analysis was done
with Kaplan-Meier and significance was determined using a log-rank test. Analysis was
performed using XLSTAT 2008 (Addinsoft, 2008) for Microsoft Excel.
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TABLES
Table 1. Recipient & Donor demographics and baseline (pre-OLT) characteristics
Donor Variables
Donor Age (years), mean± SD
Donor Sex (M/F), n
Donor Race, n
Donor HCV +, n
Recipient Variables
Age, (years), mean ± SE
Sex (M/F), n
Race, n
* Primary Diagnosis: n

MELD Score, mean ± SD
DM, n
Hypertension, n
Weight (lbs), mean ± SD
Recipient Peri-operative Data
(mean ± SE)
Cold ischemia time (h:min)
Intra-operative red blood cell
transfusion (units)

Group A
48.1 ± 4.3
12 /8
Caucasian: 13
Non-Caucasian: 7
1

Group B
45.5 ± 3.5
12 / 7
Caucasian: 13
Non-Caucasian: 6
3

p-value
ns
ns
ns

50.40 ± 
15 / 5
Caucasian: 16
Non-Caucasian: 4
Cryptogenic: 2
HCV: 11
HBV: 2
PSC: 2
HCC: 10
LC: 3
NASH: 1
23.2 ± 1.5
5
7
173.8 ± 9.6

56.2 ± 1.1
14 / 5
Caucasian: 16
Non-Caucasian: 3
Cryptogenic: 1
HCV: 14
HBV: 2
Budd-Chiari: 1
HCC: 11
LC: 6

0.05
ns
ns

24.4 ± 2
4
7
171.5 ± 7.7

ns
ns
ns
ns

7:25 ± 0:23
7.9 ± 1.6

7:52 ± 0:38
9.5 ± 1.5

ns
ns

ns

ns

Total OR time (h:mm)
Intensive care unit (days)
Hospital length of stay (days)

9:10 ± 1:19
3.6 ± 0.39
16.7 ± 1.7

8:44 ± 1:17
5.8 ± 1.27
28.6 ± 5.1

19
ns
ns
0.04

* Some patients presented multiple diagnoses. HCV, hepatitis C virus; PSC, primary
sclerosing cholangitis; HCC, hepatocellular carcinoma; HBV, hepatitis B virus; NASH,
nonalcoholic steatohepatitis; LC, Laennec’s cirrhosis

Table 2. Recipient Metabolic Panels

Clinical Variables
Liver function tests
Peak AST (IU/L)
Peak ALT (IU/L)
Total Bilirubin (mg/dl)
INR
Mean weight (lbs)
Baseline
1-month post-OLT
3-months post-OLT
6-months post-OLT
12-months post-OLT
Cholesterol (mg/dl)
Baseline
1-month post-OLT
3-months post-OLT
6-months post-OLT
12-months post-OLT
Mean arterial pressure (MAP)
Baseline
1-month post-OLT
3-months post-OLT
6-months post-OLT
12-months post-OLT
Fasting blood sugar (mg/dl)
Baseline
1-month post-OLT
3-months post-OLT

Group A

Group B

p-value

2,357
1,151
9.5
2.61

1,503
813
11.8
2.79

ns
ns
ns
ns

174
165
168
176
181

167
163
157
156
157

ns
ns
ns
ns
ns

94
155
151
165
146

91
157
143
149
160

ns
ns
ns
ns
ns

84
93
99
98
96

89
96
91
94
91

ns
ns
ns
ns
ns

148
111
117

148
103
106

ns
ns
ns

6-months post-OLT
12-months post-OLT

144
147

20
0.02
ns

98
112

Table 3. Hepatitis Recurrence

Clinical Variables
Total number of HCV recipients
Mean HCV RNA PCR
Pre-OLT
2 weeks post-OLT
1 month post-OLT
3 months post-OLT
6 months post-OLT
Treatment for HCV recurrence
No Treatment for HCV recurrence
Mean duration of treatment (wks)
Sustained viral response (SVR)
Non-responder to treatment
HCV progression to cirrhosis
Mean OLT to death interval (months)

Group A
11/20 (55%)

Group B
14/19 (74%)

p-value
ns

0.48 M
5.8 M
15.9 M
12.3 M
11.1 M
7/11 (64%)
4/11 (36%)
38.5 (4-52)
2/11 (18%)
3/11 (27%)
3/11 (27%)
25.9

0.45 M
0.83 M
3.7 M
11.9 M
5.5 M
9/14 (64%)
5/14 (36%)
19.3 (2-46)
2/14 (14%)
3/14 (21%)
4/14 (29%)
25.4

ns
ns
ns
ns
ns
ns
ns
0.048
ns
ns
ns
ns
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